MannKind Now Covered by Analysts at Cowen & Co. (MNKD)

Equities researchers at Cowen & Co assumed coverage on shares of MannKind (NASDAQ: MNKD) in a report issued on Friday. The firm set a “neutral” rating on the stock.

MannKind opened at 2.18 on Friday. MannKind has a 1-year low of $2.14 and a 1-year high of $4.75. The company’s market cap is $267.1 million.

The company last announced its quarterly results on Wednesday, February 22nd. It reported ($0.30) earnings per share (EPS) for the previous quarter, beating the Thomson Reuters consensus estimate of ($0.32) EPS by $0.02. Analysts expect that MannKind will post $-0.23 EPS next quarter.

Several other analysts have also recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of MannKind in a research note to investors on Friday, February 24th. They now have a $2.25 price target on the stock. Separately, analysts at JMP Securities cut their price target on shares of MannKind from $7.00 to $5.00 in a research note to investors on Thursday, February 23rd. They now have an “outperform” rating on the stock. Finally, analysts at Piper Jaffray (NYSE: PJC) initiated coverage on shares of MannKind in a research note to investors on Monday, February 13rd. They set an “overweight” rating on the stock.

MannKind Corporation (MannKind) is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases, such as diabetes and cancer.

http://localizedusa.com/2012/04/13/mannkind-now-covered-by-analysts-at-cowen-co-mnkd/